## **SUPPLEMENT**

## Risk factors for severe PCR-positive SARS-CoV-2 infection in hospitalized children: a multicenter cohort study

## **Supplementary Methods**

- **eTable 1.** Multivariable logistic regression models focusing only on baseline characteristics as risk factors for severe PCR-positive SARS-CoV-2 infection (WHO COVID-19 clinical progression scale of  $\geq$ 6)
- **eTable 2**. Demographic and clinical characteristics of patients PCR-positive SARS-CoV-2 infection (n=403) according to severity of disease (WHO COVID-19 clinical progression scale of >6 and/or ICU admission)
- **eTable 3** Age stratified univariable logistic regression analysis among children aged younger than 12 years (n=308) and adolescents 12 years of age and older (n=93) for severe PCR-positive SARS-CoV-2 infection (WHO COVID-19 clinical progression scale of ≥6)
- **eTable 4.** Demographic and clinical characteristics among children aged less than 12 years (n=308) according to according to severity of disease (WHO COVID-19 clinical progression scale of ≥6)
- **eTable 5.** Demographic and clinical characteristics among adolescents aged 12 to 17 years (n=93) according severity of disease (WHO COVID-19 clinical progression scale of ≥6)
- **eTable 6.** Multivariable logistic regression models for factors associated with severe PCR-positive SARS-CoV-2 infection (WHO COVID-19 progression scale of ≥6), stratified according to age groups
- **eTable 7.** Demographic and clinical characteristics among non-MIS-C patients (n=322) with PCR-positive SARS-CoV-2 infection, according to severity of disease (WHO COVID-19 clinical progression scale of ≥6)
- **eTable 8.** Multivariable logistic regression models among non-MIS-C patients for factors associated with severe PCR-positive SARS-CoV-2 infection (WHO COVID-19 clinical progression scale of  $\geq$ 6).

## **Supplementary Methods**

Ethics approval was obtained from the following ethics review boards: Comité Ético Científico Hospital Nacional de Niños, San José, Costa Rica (CEC-HNN-030-2020), Iran University of Medical Sciences Ethics Review Committee (IR.IUMS.REC.1399.187), The Hospital for Sick Children Research Ethics Board (#1000070091), Pediatric Panel of the Research Ethics Board of the Research Institute of the McGill University Health Centre (#MP-37-2021-6561), Conjoint Health Research Ethics Board, University of Calgary (REB20-0594), Children's Hospital of Eastern Ontario Research Ethics Board (CHEOREB# 20/32X), University of British Columbia Children's and Women's Research Ethics Board (# H20-00977), Health Research Ethics Board, University of Manitoba (HSC23858), University of Saskatchewan Biomedical Research Ethics Board (Study 1921), Hamilton Integrated Research Ethics Board (ID 11240), Centre Hospitalier Universitaire de Québec-Université Laval (37-2021-6561), and Health Research Ethics Board, University of Alberta (Pro00099426), CHU Sainte-Justine, Université de Montréal (MEO-37-2021-3123), Lawson Health Research Institute (ReDA ID 9857), Trillium Health Partners Research Ethics Board (#1002), Queen's University Health Sciences & Affiliated Teaching Hospitals Research Ethics Board (#6029527), IWK Research Ethics Board (#1026214). Newfoundland and Labrador Health Research Ethics Board (# 2020.047)

Classification of chronic health condition was the following: neurological, cardiac, pulmonary (including asthma), metabolic (including diabetes mellitus), renal, and chromosomal disorders; immunosuppression (including malignancy), obesity, prematurity (<37 weeks gestational age), anemia and/or hemoglobinopathy and 'other' comorbidities which included patients who could not be classified into the previous categories.

**eTable 1.** Multivariable logistic regression models focusing only on baseline characteristics as risk factors for severe PCR-positive SARS-CoV-2 infection (WHO COVID-19 clinical progression scale of ≥6). (n=401)

Model 1 incorporates the number of comorbidities, model 2 selected individual comorbidities

Covariates	Model 1	Model 2
	aOR (95% CI)	aOR (95% CI)
Age category		
<1 year	Ref.	Ref.
1-4 years	1.41 (0.71-2.79)	1.45 (0.73-2.86)
5-11 years	1.52 (0.75-3.05)	1.32 (0.65-2.68)
≥12 years	2.22 (1.12-4.40)	1.41 (0.66-3.00)
Comorbidities		
None	Ref.	-
1 comorbidity	1.32 (0.76-2.29)	-
Multiple (≥2) comorbidities	2.00 (1.09-3.65)	-
Obesity	-	3.42 (1.66-7.06)
Anemia or hemoglobinopathy	-	3.14 (1.00-9.88)
Neurological disorders	-	2.12 (1.13-3.95)

aOR adjusted odds ratio; CI confidence intervals

**eTable 2**. Demographic and clinical characteristics of patients PCR-positive SARS-CoV-2 infection (n=403) according to severity of disease (WHO COVID-19 clinical progression scale of  $\geq 6$  and/or ICU admission)

	Mild/Moderate Disease* N=275 (%)	Severe Disease and/or ICU admission* N=128 (%)	p-value**
Demographics			
Median Age in years (IQR) <sup>1</sup>	3.09 (0.30-10.10)	6.04 (1.24-12.67)	0.004
Age ≤30 days	30 (81.1%)	7 (18.9%)	0.115
Age category <sup>1</sup>			
<1 year	88 (77.9%)	25 (22.1%)	
1-4 years	74 (69.8%)	32 (30.2%)	0.024
5-11 years	55 (61.8%)	34 (38.2%)	0.024
≥12 years	56 (60.2%)	37 (39.8%)	
Male sex	157 (69.2%)	70 (30.8%)	0.730
Admission period			
Prior to July 1, 2020	14 (73.7%	5 (26.3%)	
July 1, 2020 to Dec 31, 2020	108 (71.5%)	43 (28.5%)	0.438
Jan 1, 2021 to May 31, 2021	153 (65.7%)	80 (34.3%)	
Admitted in Canada	175 (65.8%)	91 (34.2%)	0.174
Number of Comorbidities			
None	157 (72.7%)	59 (27.3%)	0.051
At least 1 comorbidity	118 (63.1%)	69 (36.9%)	0.051
Multiple (≥2) comorbidities	42 (56.0%)	33 (44.0%)	0.017
None	157 (72.7%)	59 (27.3%)	
1 comorbidity	76 (67.8%)	36 (32.1%)	0.028
Multiple (≥2) comorbidities	42 (56.0%)	33 (44.0%)	
Individual comorbidities <sup>2</sup>			
Obesity	24 (48.0%)	26 (52.0%)	0.002
Pulmonary disorders	32 (59.2%)	22 (40.7%)	0.172
Non-asthma pulmonary disorders <sup>3</sup>	10 (45.4%)	12 (54.5%)	0.034
Asthma	22 (68.7%)	10 (31.2%)	1.0
Prematurity (<37 weeks gestational age)	17 (56.7%)	13 (43.3%)	0.226
Immunosuppression	26 (83.9%)	5 (16.1%)	0.069
Malignancy <sup>4</sup>	15 (93.7%)	1 (6.2%)	0.027
Anemia or hemoglobinopathy <sup>5</sup>	7 (53.8%)	6 (43.1%)	0.406
Sickle cell anemia	4 (66.7%)	2 (33.3%)	1.0
Neurological disorders <sup>6</sup>	30 (53.6%)	26 (46.4%)	0.017
Cardiac disorders	12 (63.1%)	7 (36.8%)	0.814
Metabolic disorders	6 (50.0%)	6 (50.0%)	0.288
Diabetes mellitus	2 (40.0%)	3 (60.0%)	0.332
Renal disorders	7 (50.0%)	7 (50.0%)	0.230
Hypertension	4 (44.4%)	5 (55.5%)	0.150
Chromosomal disorders <sup>7</sup>	3 (37.5%)	5 (62.5%)	0.116
Other <sup>8</sup>	13 (52.0%)	12 (48.0%)	0.114
Clinical Features			
Fever prior to or during admission <sup>9</sup>	207 (68.5%)	95 (31.4%)	0.445

Cough	135 (64.9%)	73 (35.1%)	0.168
Shortness of breath	100 (53.2%)	88 (46.8%)	<0.001
Vomiting	83 (65.3%)	44 (34.6%)	0.466
Rhinitis	90 (72.0%)	35 (28.0%)	0.331
Diarrhea		` ′	-
	81 (70.4%)	34 (29.6%)	0.631
Abdominal pain	70 (64.8%)	38 (35.2%)	0.440
Headache	46 (63.9%)	26 (36.1%)	0.462
Rash	45 (65.2%)	24 (34.8%)	0.653
Conjunctivitis	39 (57.3%)	29 (42.6%)	0.049
Myalgia	40 (66.7%)	20 (33.3%)	0.894
Pharyngitis	46 (76.7%)	14 (23.3%)	0.171
Wheeze	34 (63.0%)	20 (37.0%)	0.461
Chest pain	26 (66.7%)	13 (33.3%)	0.967
Cracked lips	22 (57.9%)	16 (42.1%)	0.209
Edema of hands and feet	16 (59.2%)	11 (40.7%)	0.410
Anosmia	8 (66.7%)	4 (33.3%)	1.0
Seizures	5 (45.4%)	6 (54.5%)	0.111
Coinfections			
Bacterial (positive cultures) <sup>10</sup>	13 (54.2%)	11 (45.8%)	0.193
Viral	15 (46.9%)	17 (53.1%)	0.012
Bacterial and/or viral	28 (51.8%)	26 (48.1%)	0.009
Imaging			
No chest imaging performed	86 (94.5%)	5 (5.5%)	
CXR and/or CT chest normal or had findings unrelated to COVID-19	96 (79.3%)	25 (20.7%)	<0.001
CXR and/or CT chest abnormalities compatible with COVID-19	93 (48.7%)	98 (51.3%)	
Laboratory investigations			
Leukopenia (<4 X10 <sup>9</sup> /L) <sup>11</sup>	44 (74.6%)	15 (25.4%)	0.239
Leukocytosis (>15x10 <sup>9</sup> /L) <sup>11</sup>	30 (63.8%)	17 (36.2%)	0.731
Neutropenia (<1.5x 10 <sup>9</sup> /L) <sup>12</sup>	68 (80.9%)	16 (19.0%)	
Normal neutrophil count <sup>12</sup>	131 (72.0%)	51 (28.0%)	< 0.001
Neutrophilia <sup>12</sup>	56 (48.3%)	60 (51.7%)	
Thrombocytopenia (<100 x 10 <sup>9</sup> /L) <sup>13</sup>	22 (52.4%)	20 (47.6%)	
Normal platelet count <sup>13</sup>	189 (72.4%)	72 (27.6%)	0.004
Thrombocytosis (>450 x 10 <sup>9</sup> /L) <sup>13</sup>	47 (57.3%)	35 (42.7%)	
CRP not done <sup>14</sup>	49 (81.7%)	11 (18.3%)	
Normal CRP <sup>14</sup>	165 (73.7%)	59 (26.3%)	<0.001
CRP >50 (mg/L) <sup>14</sup>	61 (51.3%)	58 (48.7%)	7
Ferritin >500 (mcg/L) <sup>15</sup>	24 (43.6%)	31 (56.4%)	0.160
Albumin<29 (g/L) <sup>16</sup>	17 (36.9%)	29 (63.0%)	<0.001
Complications	(======================================	(/	13352
MIS-C diagnosis	44 (54.3%)	37 (45.7%)	0.004
CT computed tomography: CPD C reactive protein:	` ′	, ,	

CT computed tomography; CRP C-reactive protein; CXR chest x-ray; IQR interquartile range; MIS-C multisystem inflammatory syndrome in children

<sup>\*</sup> Percentages were calculated for the row, i.e., % of a stratum with severe or mild/moderate disease.

<sup>\*\*</sup> Comparisons performed using chi squared or Fisher's exact test as appropriate for categorical data and Wilcoxon rank sum test for continuous data as appropriate.

- <sup>1</sup> A total of 2 children with mild/moderate disease are missing date of birth.
- <sup>2</sup> Children are listed more than once if they had more than one comorbidity.
- <sup>3</sup> Clinical information is available for 14/22 patients: obstructive sleep apnea (n=5); bronchopulmonary dysplasia (n=3); pulmonary hypertension (n=2); cystic fibrosis (n=1); chronic aspiration pneumonia (n=1); subglottic stenosis (n=1); Pierre-Robin anomaly (n=1)
- <sup>4</sup> Malignancy consists of the following: acute lymphoblastic leukemia (n=11); neuroblastoma (n=2); lymphoma (n=1); rhabdomyosarcoma (n=1); and osteosarcoma (n=1)
- <sup>5</sup> Anemia and/or hemoglobinopathy consist of the following: sickle cell disease (n=6); Glucose-6-phosphate dehydrogenase deficiency (n=2); anemia of chronic disease (n=2); ovalocytosis (n=1); pancytopenia of unknown etiology (n=1); iron deficient anemia (n=1)
- <sup>6</sup> Additional information is available for 47/56 patients: syndromic condition with global developmental delay (GDD) (n=19); autism and/or GDD of unexplained etiology (n=10); cerebral palsy (n=7); muscular dystrophy (n=3); hydrocephalus (n=2); congenital microcephaly (n=2); brain tumor (n=1); focal cortical dysplasia (n=1); encephalopathy (n=1); epilepsy (n=1)
- <sup>7</sup> Additional information is available for 7/8 patients: Trisomy 21 (n=3); unbalanced translocation (n=2); Prader-Willi syndrome (n=1); Miller-Dieker syndrome (n=1)
- <sup>8</sup> Other consists of the following: gastrostomy (n=12); liver transplantation (n=2); celiac disease (n=1); Crohn's disease (n=1) failure to thrive (n=1); inflammatory bowel disease (n=1); inflammatory bowel disease and Hirschsprung disease (n=1); unclear liver disease (n=1); esophageal atresia (n=1); scoliosis (n=2); liver cirrhosis & cholestasis (n=1); Glanzmann thrombasthenia (n=1)
- <sup>9</sup> A total of 35 children were missing data on fever prior to or during admission (19 with mild/moderate disease and 16 with severe disease) resulting in a total N of 368.
- <sup>10</sup> Children with one of the following are included: blood culture thought to be truly positive and/or positive endotracheal tube cultures treated with antibiotics for presumptive bacterial pneumonia and/or positive bacterial culture from another site treated with antibiotics.
- <sup>11</sup> A total of 17 children were missing leukocyte values (16 with mild/moderate disease and 1 with severe disease) resulting in a total N of 386.
- <sup>12</sup> A total of 21 children were missing neutrophil values (20 with mild/moderate disease and 1 with severe disease) resulting in a total N of 382. Cut-off values for neutrophilia are age dependent.
- <sup>13</sup> A total of 18 children were missing a platelet value (17 with mild/moderate disease and 1 with severe disease) resulting in a total N of 385.
- <sup>14</sup> A total of 60 children were missing a CRP value (49 with mild/moderate disease and 11 with severe disease) resulting in a total N of 343.
- <sup>15</sup> The highest ferritin value measured variable used and a total of 220 children were missing a value (179 with mild/moderate disease and 41 with severe disease) resulting in a total N of 183.
- <sup>16</sup> A total of 271 children were missing albumin values (199 with mild/moderate disease and 72 with severe disease) resulting in a total N of 132.

**eTable 3** Age stratified univariable logistic regression analysis among children aged younger than 12 years (n=308) and adolescents 12 years of age and older (n=93) for severe PCR-positive SARS-CoV-2 infection (WHO COVID-19 clinical progression scale of ≥6)

	Unadjusted OR among those younger than 12 years of age N=308	Unadjusted OR among those 12 years of age and older N=93
27 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	OR (95% CI)	OR (95% CI)
Number of comorbidities		
None	Ref.	Ref.
1 comorbidity	1.14 (0.58-2.25)	1.78 (0.65-4.87)
Multiple (≥2) comorbidities	2.85 (1.45-5.58)	1.22 (0.39-3.86)
Individual comorbidities		
Obesity	3.70 (1.15-11.86)	2.93 (1.22-7.05)
Pulmonary disorders	2.38 (1.17-4.82)	0.69 (0.20-2.40)
Non-asthma pulmonary disorders	4.33 (1.60-11.70)	0.44 (0.05-4.08)
Anemia or hemoglobinopathy	3.03 (0.90-10.26)	1.84 (0.11-30.47)
Neurological disorders	2.74 (1.33-5.63)	1.42 (0.51-3.99)
Cardiac disorders	2.43 (0.83-7.09)	-
Hypertension	3.57 (0.70-18.13)	3.81 (0.33-43.65)
Chromosomal disorders	4.84 (1.06-22.18)	-
Clinical Features	, ,	
Fever prior to or during admission	0.86 (0.42-1.77)	4.05 (0.84-19.44)
Shortness of breath	5.98 (3.30-10.86)	3.73 (1.26-11.02)
Conjunctivitis	1.63 (0.85-3.10)	1.61 (0.45-5.73)
Pharyngitis	0.40 (0.13-1.17)	0.52 (0.18-1.47)
Wheeze	1.86 (0.94-3.70)	0.71 (0.13-3.88)
Seizures	2.88 (0.75-11.03)	1.84 (0.11-30.47)
Coinfections	2.00 (0.73 11.03)	1.04 (0.11 30.47)
Bacterial and/or viral	4.11 (2.10-8.02)	1.24 (0.32-4.76)
	4.11 (2.10-0.02)	1.24 (0.32-4.70)
CXR and/or CT normal or had findings unrelated to COVID-19	Ref.	Ref.
No chest imaging done	0.07 (0.01-0.52)	0.54 (0.04-6.77)
CXR or CT abnormalities compatible with COVID-19	3.57 (1.90-6.70)	5.57 (1.16-26.69)
Laboratory investigations		
Neutropenia (<1.5x 10 <sup>9</sup> /L)	0.72 (0.32-1.66)	1.38 (0.42-4.52)
Normal neutrophil count	Ref.	Ref.
Neutrophilia	3.02 (1.64-5.58)	3.23 (1.17-8.94)
Thrombocytopenia		
$(<100 \times 10^9/L)$	1.79 (0.78-4.07)	1.10 (0.24-5.01)
Normal platelet count	Ref.	Ref.
Thrombocytosis (>450 x 10 <sup>9</sup> /L)	1.66 (0.89-3.09)	2.30 (0.56-9.35)
CRP not done	Ref.	Ref.
Normal CRP	1.18 (0.53-2.65)	-
CRP >50 (mg/L)	2.04 (0.86-4.84)	-
Complications		
MIS-C Note Among those less than 12 years of age. N for	1.52 (0.81-2.85)	1.60 (0.56-4.55)

Note. Among those less than 12 years of age, N for model with fever is 281 as 27 deleted due to missingness, N for models with neutrophil counts are 292 as 16 deleted due to missingness, N for models with platelet counts

are 295 as 13 deleted due to missingness. Among those 12 years of age and older, N for model with fever is 86 as 7 deleted due to missingness, N for models with neutrophil counts and platelet counts are 88 as 5 deleted due to missingness.

OR odds ratio; CT computed tomography; CRP C-reactive protein; CXR chest x-ray; IQR interquartile range; MIS-C multisystem inflammatory syndrome in children

**eTable 4.** Demographic and clinical characteristics among children aged less than 12 years (n=308) according to according to severity of disease (WHO COVID-19 clinical progression scale of ≥6)

	Mild/Moderate Disease* N=239 (%)	Severe Disease* N=69 (%)	p-value**
Demographics	( ,		
Male sex	136 (76.8%)	41 (23.2%)	0.815
Admission period			
Prior to July 1, 2020	13 (81.2%)	3 (18.7%)	
Between July 1, 2020 to Dec 31, 2020	97 (78.2%)	27 (21.8%)	0.973
Between Jan 1, 2021 to May 31, 2021	129 (76.8%)	39 (23.2%)	
Admitted in Canada	138 (77.5%)	40 (22.5%)	1.0
Number of Comorbidities			
None	150 (81.5%)	34 (18.5%)	0.061
At least 1 comorbidity	89 (71.8%)	35 (28.2%)	0.061
Multiple (≥2) comorbidities	31 (60.8%)	20 (39.2%)	0.001
None	150 (81.5%)	34 (18.5%)	
1 comorbidity	58 (79.4%)	15 (20.5%)	0.007
Multiple ( <u>&gt;</u> 2) comorbidities	31 (60.8%)	20 (39.2%)	
Individual comorbidities <sup>1</sup>			
Obesity	6 (50.0%)	6 (50.0%)	0.047
Pulmonary disorders	25 (62.5%)	15 (37.5%)	0.024
Non-asthma pulmonary disorders	8 (47.0%)	9 (52.9%)	0.005
Asthma	17 (73.9%)	6 (26.1%)	0.857
Prematurity (<37 weeks gestational age)	20 (71.4%)	8 (28.6%)	0.560
Immunosuppression	18 (81.8%)	4 (18.2%)	0.793
Cancer	12 (92.3%)	1 (7.7%)	0.310
Anemia or hemoglobinopathy	6 (54.5%)	5 (45.4%)	0.073
Sickle cell anemia	3 (75.0%)	1 (25.0%)	1.0
Neurological disorders	22 (59.4%)	15 (40.5%)	0.009
Cardiac disorders	9 (60.0%)	6 (40.0%)	0.174
Metabolic disorders	5 (83.3%)	1 (16.7%)	1.0
Diabetes mellitus	1 (100.0%)	0	1.0
Renal disorders	7 (58.3%)	5 (41.7%)	0.201
Hypertension	3 (50.0%)	3 (50.0%)	0.128
Chromosomal disorders	3 (42.8%)	4 (57.1%)	0.047
Other	11 (64.7%)	6 (35.3%)	0.311
Clinical Features			
Fever prior to or during admission <sup>2</sup>	182 (79.5%)	47 (20.5%)	0.826
Cough	104 (75.4%)	34 (24.6%)	0.478
Shortness of breath	73 (59.3%)	50 (40.6%)	< 0.001
Vomiting	67 (72.8%)	25 (27.2%)	0.245
Rhinitis	84 (77.8%)	24 (22.2%)	1.0
Diarrhea	64 (77.1%)	19 (22.9%)	1.0
Abdominal pain	61 (76.2%)	19 (23.7%)	0.857
Headache	33 (75.0%)	11 (25.0%)	0.802

Rash	44 (74.6%)	15 (25.4%)	0.656
Conjunctivitis	40 (70.2%)	17 (29.8%)	0.189
Myalgia	31 (79.5%)	8 (20.5%)	0.922
Pharyngitis	32 (88.9%)	4 (11.1%)	0.092
Wheeze	31 (67.4%)	15 (32.6%)	0.108
Chest pain	11 (73.3%)	4 (26.7%)	0.751
Cracked lips	24 (72.7%)	9 (27.3%)	0.625
Edema of hands and feet	16 (72.7%)	6 (27.3%)	0.762
Anosmia	4 (100.0%)	0	0.578
Seizures	5 (55.5%)	4 (44.4%)	0.117
Coinfections			
Bacterial (positive cultures) <sup>3</sup>	10 (55.5%)	8 (44.4%)	0.043
Viral	13 (46.4%)	15 (53.6%)	< 0.001
Bacterial and/or viral	23 (52.3%)	21 (47.7%)	<0.001
Imaging			
No chest imaging done	77 (98.7%)	1 (1.3%)	
CXR and/or CT chest normal or had findings unrelated to COVID-19	88 (83.8%)	17 (16.2%)	<0.001
CXR and/or CT chest abnormalities compatible with COVID-19	74 (59.2%)	51 (40.8%)	
Laboratory investigations			
Leukopenia (<4 X10 <sup>9</sup> /L) <sup>4</sup>	33 (91.7%)	3 (8.3%)	0.033
Leukocytosis (>15x10 <sup>9</sup> /L) <sup>4</sup>	30 (71.4%)	12 (28.6%)	0.472
Neutropenia (<1.5x 10 <sup>9</sup> /L) <sup>5</sup>	58 (86.6%)	9 (13.4%)	
Normal neutrophil count <sup>5</sup>	112 (82.3%)	24 (17.6%)	< 0.001
Neutrophilia <sup>5</sup>	54 (60.7%)	35 (39.3%)	
Thrombocytopenia (<100 x 10 <sup>9</sup> /L) <sup>6</sup>	23 (69.7%)	10 (30.3%)	
Normal platelet count <sup>6</sup>	152 (80.4 %)	37 (19.6%)	0.164
Thrombocytosis (>450 x 10 <sup>9</sup> /L) <sup>6</sup>	52 (71.2%)	21 (28.8%)	
CRP not done <sup>7</sup>	42 (82.3%)	9 (17.6%)	
Normal CRP <sup>7</sup>	142 (79.8%)	36 (20.2%)	0.133
$CRP > 50 \text{ (mg/L)}^7$	55 (69.6%)	24 (30.4%)	
Ferritin >500 (mcg/L) <sup>8</sup>	24 (63.1%)	14 (36.8%)	0.523
Albumin<29 (g/L) <sup>9</sup>	21 (56.7%)	16 (43.2%)	0.033
Complications			
MIS-C diagnosis	45 (71.4%)	18 (28.6%)	0.251

CT computed tomography; CRP C-reactive protein; CXR chest x-ray; MIS-C multisystem inflammatory syndrome in children

<sup>\*</sup> Percentages were calculated for the row, i.e., % of a stratum with severe or mild/moderate disease.

<sup>\*\*</sup> Comparisons performed using chi squared or Fisher's exact test as appropriate for categorical data.

<sup>&</sup>lt;sup>1</sup> Children are listed more than once if they had more than one comorbidity.

<sup>&</sup>lt;sup>2</sup> A total of 27 children were missing data on fever prior to or during admission (17 with mild/moderate disease and 10 with severe disease) resulting in a total N of 281.

<sup>&</sup>lt;sup>3</sup> Children with one of the following are included: blood culture thought to be truly positive and/or positive endotracheal tube cultures treated with antibiotics for presumptive bacterial pneumonia and/or positive bacterial culture from another site treated with antibiotics.

<sup>&</sup>lt;sup>4</sup> A total of 13 children were missing leukocyte values (12 with mild/moderate disease and 1 with severe disease) resulting in a total N of 295.

- <sup>5</sup> A total of 16 children were missing neutrophil values (15 with mild/moderate disease and 1 with severe disease) resulting in a total N of 292. Cut-off values for neutrophilia are age dependent
- $^6$  A total of 13 children were missing platelet values (12 with mild/moderate disease and 1 with severe disease) resulting in a total N of 295.
- <sup>7</sup> A total of 51 children were missing a CRP value (42 with mild/moderate disease and 9 with severe disease) resulting in a total N of 257.
- <sup>8</sup> The highest ferritin value measured variable used and a total of 181 children were missing a value (152 with mild/moderate disease and 29 with severe disease) resulting in a total N of 127.
- <sup>9</sup> A total of 205 children were missing albumin values (166 with mild/moderate disease and 39 with severe disease) resulting in a total N of 103.

**eTable 5.** Demographic and clinical characteristics among adolescents aged 12 to 17 years (n=93) according severity of disease (WHO COVID-19 clinical progression scale of ≥6)

	Mild/Moderate Disease*	Severe Disease*	p-value**
D 1'	N=60 (%)	N=33 (%)	
Demographics Malacan American	24 (60 40/)	15 (20 (0))	0.412
Male sex	34 (69.4%)	15 (30.6%)	0.413
Admission period	2 (100 00()	0	
Prior to July 1, 2020	3 (100.0%)	0	0.44
Between July 1, 2020 to Dec 31, 2020	20 (76.9%)	6 (23.1%)	0.112
Between Jan 1, 2021 to May 31, 2021	37 (57.8%)	27 (42.2%)	
Admitted in Canada	56 (64.4%)	31 (35.6%)	1.0
Number of comorbidities			
None	22 (71.0%)	9 (29.0%)	0.490
At least 1 comorbidity	38 (61.3%)	24 (38.7%)	0.150
Multiple ( $\geq$ 2) comorbidities	16 (66.7%)	8 (33.3%)	0.994
None	22 (71.0%)	9 (29.0%)	
1 comorbidity	22 (57.9%)	16 (42.1%)	0.512
Multiple ( $\geq 2$ ) comorbidities	16 (66.7%)	8 (33.3%)	
Individual comorbidities <sup>1</sup>			
Obesity	19 (50.0%)	19 (50.0%)	0.027
Pulmonary disorders	10 (71.4%)	4 (28.6%)	0.763
Non-asthma pulmonary disorders	4 (80.0%)	1 (20.0%)	0.652
Asthma	6 (66.7%)	3 (33.3%)	1.0
Prematurity (<37 weeks gestational age)	0	2 (100.0%)	0.123
Immunosuppression	7 (87.5%)	1 (12.5%)	0.252
Cancer	2 (100.0%)	0	0.537
Anemia or hemoglobinopathy	1 (50.0%)	1 (50.0%)	1.0
Sickle cell anemia	1 (50.0%)	1 (50.0%)	1.0
Neurological disorders	11 (57.9%)	8 (42.1%)	0.684
Cardiac disorders	4 (100.0%)	0	0.293
Metabolic disorders	3 (50.0%)	3 (50.0%)	0.662
Diabetes mellitus	2 (50.0%)	2 (50.0%)	0.613
Renal disorders	2 (100.0%)	0	0.537
Hypertension	1 (33.3%)	2 (66.7%)	0.286
Chromosomal disorders	0	1 (100.0%)	0.355
Other	6 (75.0%)	2 (25.0%)	0.707
Clinical Features	0 (72.070)	2 (201070)	0.707
Fever prior to or during admission <sup>2</sup>	43 (59.7%)	29 (40.3%)	0.075
Cough	41 (60.3%)	27 (39.7%)	0.075
Shortness of breath	36 (56.2%)	28 (43.7%)	0.019
Vomiting	23 (67.6%)	11 (32.3%)	0.799
Rhinitis	12 (75.0%)	4 (25.0%)	0.401
Diarrhea	23 (71.9%)	9 (28.1%)	0.401
Abdominal pain	19 (67.8%)	9 (28.1%)	0.397
1	` ′	` '	
Headache	19 (67.8%)	9 (32.1%)	0.837
Rash	6 (60.0%)	4 (40.0%)	0.739
Conjunctivitis	6 (54.5%)	5 (45.4%)	0.512

15 (71.4%)	6 (28.6%)	0.622
18 (75.0%)	6 (25.0%)	0.318
5 (71.4%)	2 (28.6%)	1.0
16 (66.7%)	8 (33.3%)	0.994
2 (40.0%)	3 (60.0%)	0.343
3 (60.0%)	2 (40.0%)	1.0
6 (75.0%)	2 (25.0%)	0.707
1 (50.0%)	1 (50.0%)	1.0
4 (66.7%)	2 (33.3%)	1.0
2 (50.0%)	2 (50.0%)	0.613
6 (60.0%)	4 (40.0%)	0.739
12 (92.3%)	1 (7.7%)	
13 (86.7%)	2 (13.3%)	0.0039
35 (53.8%)	30 (46.1%)	
14 (60.9%)	9 (39.1%)	1.0
1 (33.3%)	2 (66.7%)	0.552
11 (64.7%)	6 (35.3%)	
33 (71.7%)	13 (28.3%)	0.068
11 (44.0%)	14 (56.0%)	
5 (62.5%)	3 (37.5%)	
46 (64.8%)	25 (35.2%)	0.505
4 (44.4%)	5 (55.5%)	
9 (100.0%)	0	
30 (68.2%)	14 (31.8%)	0.0147
21 (52.5%)	19 (47.5%)	
6 (35.3%)	11 (64.7%)	0.281
3 (33.3%)	6 (66.7%)	0.106
, ,		
10 (55.5%)	8 (44.4%)	0.541
	18 (75.0%) 5 (71.4%) 16 (66.7%) 2 (40.0%) 3 (60.0%) 6 (75.0%) 1 (50.0%) 4 (66.7%) 2 (50.0%) 6 (60.0%)  12 (92.3%) 13 (86.7%) 35 (53.8%)  14 (60.9%) 1 (33.3%) 11 (64.7%) 33 (71.7%) 11 (44.0%) 5 (62.5%) 46 (64.8%) 4 (44.4%) 9 (100.0%) 30 (68.2%) 21 (52.5%) 6 (35.3%) 3 (33.3%)	18 (75.0%)       6 (25.0%)         5 (71.4%)       2 (28.6%)         16 (66.7%)       8 (33.3%)         2 (40.0%)       3 (60.0%)         3 (60.0%)       2 (40.0%)         6 (75.0%)       2 (25.0%)         1 (50.0%)       1 (50.0%)         4 (66.7%)       2 (33.3%)         2 (50.0%)       2 (50.0%)         6 (60.0%)       4 (40.0%)         12 (92.3%)       1 (7.7%)         13 (86.7%)       2 (13.3%)         35 (53.8%)       30 (46.1%)         14 (60.9%)       9 (39.1%)         1 (33.3%)       2 (66.7%)         11 (64.7%)       6 (35.3%)         33 (71.7%)       13 (28.3%)         11 (44.0%)       14 (56.0%)         5 (62.5%)       3 (37.5%)         46 (64.8%)       25 (35.2%)         4 (44.4%)       5 (55.5%)         9 (100.0%)       0         30 (68.2%)       14 (31.8%)         21 (52.5%)       19 (47.5%)         6 (35.3%)       11 (64.7%)         3 (33.3%)       6 (66.7%)

CT computed tomography; CRP C-reactive protein; CXR chest x-ray; MIS-C multisystem inflammatory syndrome in children; PCR polymerase chain reaction; WHO World Health Organization.

<sup>\*</sup> Percentages were calculated for the row, i.e., % of a stratum with severe or mild/moderate disease.

<sup>\*\*</sup> Comparisons performed using chi squared or Fisher's exact test as appropriate for categorical data.

<sup>&</sup>lt;sup>1</sup> Children are listed more than once if they had more than one comorbidity.

 $<sup>^{2}</sup>$  A total of 7 children were missing data on fever prior to or during admission (5 with mild/moderate disease and 2 with severe disease) resulting in a total N of 86.

<sup>&</sup>lt;sup>3</sup> Children with one of the following are included: blood culture thought to be truly positive and/or positive endotracheal tube cultures treated with antibiotics for presumptive bacterial pneumonia and/or positive bacterial culture from another site treated with antibiotics.

<sup>&</sup>lt;sup>4</sup> A total of 4 children were missing leukocyte values (4 with mild/moderate disease) resulting in a total N of 89.

<sup>&</sup>lt;sup>5</sup> A total of 5 children were missing neutrophil values (5 with mild/moderate disease) resulting in a total N of 88. Cut-off values for neutrophilia are age dependent

<sup>&</sup>lt;sup>6</sup> A total of 5 children were missing platelet values (5 with mild/moderate disease) resulting in a total N of 88.

<sup>&</sup>lt;sup>7</sup> A total of 9 children were missing a CRP value (9 with mild/moderate disease) resulting in a total N of 84.

 $<sup>^8</sup>$  The highest ferritin value measured variable used and a total of 38 children were missing a value (33 with mild/moderate disease and 35 with severe disease) resulting in a total N of 55.

<sup>&</sup>lt;sup>9</sup> A total of 64 children were missing albumin values (43 with mild/moderate disease and 21 with severe disease) resulting in a total N of 29.

**eTable 6.** Multivariable logistic regression models for factors associated with severe PCR-positive SARS-CoV-2 infection (WHO COVID-19 progression scale of  $\geq$ 6), stratified according to age groups.

Model 1 incorporates selected individual comorbidities, model 2 the number of comorbidities while excluding individual comorbidities; both in children <12 years of age.

Model 3 is incorporates selected individual comorbidities in adolescents ≥ 12 years

	Model 1:	Model 2:	Model 3:
Covariates	Children < 12	Children < 12	Children ≥ 12 years
Covariates	years old	years old	old
	aOR (95% CI)	aOR (95% CI)	aOR (95% CI)
Number of comorbidities			
None	=	Ref.	=
1 comorbidity	=	1.57 (0.69-3.60)	=
Multiple (>2) comorbidities	-	2.60 (1.12-6.06)	-
Individual comorbidities			
Obesity	1.17 (0.29-4.67)	-	3.21 (1.15-8.93)
Non-asthma pulmonary disorders	1.68 (-0.45-6.22)	-	-
Anemia or hemoglobinopathy	-	-	-
Neurological disorders	3.16 (1.19-8.43)	-	-
Cardiac disorders	-	-	-
Hypertension	-	-	-
Chromosomal disorders	-	-	-
Coinfections			
Bacterial and/or viral	2.60 (1.13-5.99)	2.50 (1.10-5.69)	-
Imaging			
No chest imaging done	0.15 (0.02-1.24)	0.16 (0.02-1.28)	0.82 (0.05-8.93)
CXR and/or CT normal or had	Ref.	Ref.	Ref.
findings unrelated to COVID-19	Kei.	Kel.	Kei.
CXR or CT abnormalities	3.10 (1.49-6.42)	2.99 (1.45-6.18)	7.87 (1.32-46.97)
compatible with COVID-19	3.10 (1.49-0.42)	2.99 (1.45-0.18)	7.87 (1.32-40.97)
Clinical presentation			
Shortness of breath	5.02 (2.10-12.04)	5.03 (2.12-11.88)	-
Complications			
MIS-C diagnosis	4.85 (1.70-13.83)	4.92 (1.72-14.04)	1.11 (0.27-4.67)
Laboratory investigations			
Neutrophilia	1.54 (0.74-3.22)	1.55 (0.75-3.22)	5.81 (1.85-18.22)

aOR adjusted odds ratio; CI confidence interval; CT computed tomography; CXR chest x-ray; MIS-C multisystem inflammatory syndrome in children

**eTable 7.** Demographic and clinical characteristics among non-MIS-C patients (n=322) with PCR-positive SARS-CoV-2 infection, according to severity of disease (WHO COVID-19 clinical progression scale of ≥6)

	Mild/Moderate Disease* N=246 (%)	Severe Disease* N=76 (%)	p- value**	Unadjusted OR for severe disease
Demographics				
Median Age in years (IQR) <sup>1</sup>	2.08 (0.23-9.66)	3.65 (0.98- 14.41)	0.0062	1.04 (1.00-1.09)
Age ≤30 days	34 (91.9%)	3 (8.1%)	0.0218	0.26 (0.08-0.86)
Age category <sup>1</sup>				
<1 year	94 (83.2%)	19 (16.8%)		Ref.
1-4 years	61 (71.8%)	24 (28.2%)	0.0202	1.95 (0.98-3.85)
5-11 years	39 (83.0%)	8 (17.0%)	0.0303	1.01 (0.41-2.51)
≥12 years	50 (66.7%)	25 (33.3%)		2.47 (1.24-4.92)
Male sex	137 (76.5%)	42 (23.5%)	1.0	0.98 (0.58-1.65)
Admission period				
Prior to July 1, 2020	15 (88.2%)	2 (11.8%)		Ref.
Between July 1, 2020 to Dec 31, 2020	93 (79.5%)	24 (20.5%)	0.280	1.93 (0.41-9.05)
Between Jan 1, 2021 to May 31, 2021	138 (73.4%)	50 (26.6%)		2.72 (0.60- 12.31)
Admitted in Canada	158 (76.3%)	49 (23.7%)	1.0	1.01 (0.59-1.73)
Number of comorbidities				
None	128 (83.7%)	25 (16.3%)	0.0053	Ref.
At least 1 comorbidity	118 (69.8%)	51 (30.2%)		2.21 (1.29-3.80)
Multiple (≥2) comorbidities	44 (63.8%)	25 (36.2%)	0.0086	2.25 (1.26-4.01)
None	128 (83.7%)	25 (16.3%)		Ref.
1 comorbidity	74 (74.0%)	26 (26.0%)	0.0043	1.80 (0.97-3.34)
Multiple (>2) comorbidities	44 (63.8%)	25 (36.2%)	1	2.91 (1.52-5.58)
Individual comorbidities <sup>2</sup>				
Obesity	24 (55.8%)	19 (44.2%)	0.0013	3.08 (1.58-6.02)
Pulmonary disorders	32 (64.0%)	18 (36.0%)	0.0389	2.07 (1.09-3.96)
Non-asthma pulmonary disorders	12 (54.5%)	10 (45.4%)	0.0250	2.95 (1.22-7.14)
Asthma	20 (71.4%)	8 (28.6%)	0.678	1.33 (0.56-3.15)
Prematurity (<37 weeks gestational age)	19 (65.5%)	10 (34.5%)	0.223	1.81 (0.80-4.08)
Immunosuppression	24 (85.7%)	4 (14.3%)	0.350	0.51 (0.17-1.53)
Cancer	13 (92.8%)	1 (7.1%)	0.201	0.24 (0.03-1.86)
Anemia or hemoglobinopathy	7 (63.6%)	4 (36.4%)	0.295	1.90 (0.54-6.66)
Sickle cell anemia	4 (80.0%)	1 (20.0%)	1.0	0.81 (0.09-7.33)
Neurological disorders	29 (56.9%)	22 (43.1%)	<0.001	3.05 (1.62-5.72)
Cardiac disorders	13 (68.4%)	6 (31.6%)	0.572	1.54 (0.56-4.19)
Metabolic disorders	8 (72.7%)	3 (27.3%)	0.725	1.22 (0.32-4.73)
Diabetes mellitus	3 (75.0%)	1 (25.0%)	1.0	1.08 (0.11- 10.54)
Renal disorders	9 (69.2%)	4 (30.8%)	0.514	1.46 (0.44-4.89)
Hypertension	4 (50.0%)	4 (50.0%)	0.093	3.36 (0.82- 13.78)

Chromosomal disorders	2 (28.6%)	5 (71.4%)	0.0092	8.59 (1.63- 45.23)
Other	15 (65.2%)	8 (34.8%)	0.291	1.81 (0.74-4.45)
Clinical Features	- (,			(*** (***
Fever prior to or during admission <sup>3</sup>	172 (77.5%)	50 (22.5%)	0.955	1.08 (0.55-2.11)
Cough	132 (71.7%)	52 (28.3%)	0.0323	1.87 (1.08-3.23)
Shortness of breath	105 (61.0%)	67 (38.9%)	<0.001	10.00 (4.77- 20.96)
Vomiting	56 (80.0%)	14 (20.0%)	0.520	0.77 (0.40-1.47)
Rhinitis	85 (78.0%)	24 (22.0%)	0.734	0.87 (0.50-1.51)
Diarrhea	57 (82.6%)	12 (17.4%)	0.226	0.62 (0.31-1.23)
Abdominal pain	35 (81.4%)	8 (18.6%)	0.525	0.71 (0.31-1.60)
Headache	26 (78.8%)	7 (21.2%)	0.900	0.86 (0.36-2.06)
Rash	15 (78.9%)	4 (21.0%)	1.0	0.85 (0.27-2.66)
Conjunctivitis	7 (87.5%)	1 (12.5%)	0.686	0.45 (0.05-3.76)
Myalgia	30 (76.9%)	9 (23.1%)	1.0	0.97 (0.44-2.14)
Pharyngitis	32 (88.9%)	4 (11.1%)	0.063	0.37 (0.13-1.09)
Wheeze	36 (69.2%)	16 (30.8%)	0.250	1.55 (0.81-2.99)
Chest pain	26 (81.2%)	6 (18.7%)	0.644	0.72 (0.29-1.83)
Cracked lips	2 (66.7%)	1 (33.3%)	0.555	1.63 (0.14- 18.19)
Edema of hands and feet	1 (50.0%)	1 (50.0%)	0.417	3.27 (0.20- 52.86)
Anosmia	7 (87.5%)	1 (12.5%)	0.686	0.45 (0.05-3.76)
Seizures	6 (54.5%)	5 (45.4%)	0.139	2.82 (0.83-9.50)
Coinfections				
Bacterial (positive cultures) <sup>4</sup>	10 (52.6%)	9 (47.4%)	0.0253	3.17 (1.24-8.12)
Viral	13 (46.4%)	15 (53.6%)	< 0.001	4.41 (1.99-9.75)
Bacterial and/or viral	23 (51.1%)	22 (48.9%)	<0.001	3.95 (2.05-7.61)
Imaging				
No chest imaging done	72 (97.3%)	2 (2.7%)		Ref.
CXR and/or CT chest normal or had findings unrelated to COVID- 19	78 (85.7%)	13 (14.3%)	<0.001	0.17 (0.04-0.76)
CXR and/or CT chest abnormalities compatible with COVID-19	96 (61.1%)	61 (38.8%)		3.81 (1.95-7.44)
Laboratory investigations				
Leukopenia (<4 X10 <sup>9</sup> /L) <sup>5</sup>	42 (77.8%)	12 (22.2%)	0.798	0.86 (0.42-1.73)
Leukocytosis (>15x10 <sup>9</sup> /L) <sup>5</sup>	31 (77.5%)	9 (22.5%)	0.905	0.88 (0.40-1.94)
Neutropenia (<1.5x 10 <sup>9</sup> /L) <sup>6</sup>	64 (81.0%)	15 (19.0%)		0.85 (0.43-1.68)
Normal neutrophil count <sup>6</sup>	124 (78.5%)	34 (21.5%)	0.0055	Ref.
Neutrophilia <sup>6</sup>	39 (60.0%)	26 (40.0%)		2.43 (1.30-4.54)
Thrombocytopenia (<100 x 10 <sup>9</sup> /L) <sup>7</sup>	19 (73.1%)	7 (26.9%)	0.201	1.27 (0.51-3.19)
Normal platelet count <sup>7</sup>	176 (77.5%)	51 (22.5%)	0.291	Ref.
Thrombocytosis (>450 x 10 <sup>9</sup> /L) <sup>7</sup>	35 (67.3%)	17 (32.7%)		1.68 (0.87-3.24)
CRP not done <sup>8</sup>	51 (86.4%)	8 (13.5%)		Ref.
Normal CRP <sup>8</sup>	168 (77.4%)	49 (22.6%)	0.0033	1.86 (0.83-4.18)
CRP >50 (mg/L) <sup>8</sup>	27 (58.7%)	19 (41.3%)		4.49 (1.74- 11.58)

Ferritin >500 (mcg/L) <sup>9</sup>	10 (52.6%)	9 (47.4%)	0.697	1.39 (0.51-3.78)
Albumin<29 (g/L) <sup>10</sup>	4 (36.4%)	7 (63.6%)	0.0345	4.53 (1.17- 17.47)

OR, odds ratio; CT computed tomography; CRP C-reactive protein; CXR chest x-ray; IQR interquartile range; MIS-C multisystem inflammatory syndrome in children; PCR polymerase chain reaction; WHO World Health Organization.

<sup>\*</sup> Percentages were calculated for the row, i.e., % of a stratum with severe or mild/moderate disease.

<sup>\*\*</sup> Comparisons performed using chi squared or Fisher's exact test as appropriate for categorical data and Wilcoxon rank sum test for continuous data as appropriate.

<sup>&</sup>lt;sup>1</sup> A total of 2 children with mild/moderate disease are missing date of birth.

<sup>&</sup>lt;sup>2</sup> Children are listed more than once if they had more than one comorbidity.

<sup>&</sup>lt;sup>3</sup> A total of 34 children were missing data on fever prior to or during admission (22 with mild/moderate disease and 12 with severe disease) resulting in a total N of 288.

<sup>&</sup>lt;sup>4</sup> Children with one of the following are included: blood culture thought to be truly positive and/or positive endotracheal tube cultures treated with antibiotics for presumptive bacterial pneumonia and/or positive bacterial culture from another site treated with antibiotics.

<sup>&</sup>lt;sup>5</sup> A total of 16 children were missing leukocyte values (15 with mild/moderate disease and 1 with severe disease) resulting in a total N of 306.

<sup>&</sup>lt;sup>5</sup> A total of 20 children were missing neutrophil values (19 with mild/moderate disease and 1 with severe disease) resulting in a total N of 302. Cut-off values for neutrophilia are age dependent.

<sup>&</sup>lt;sup>7</sup> A total of 17 children were missing platelet values (16 with mild/moderate disease and 1 with severe disease) resulting in a total N of 305.

<sup>&</sup>lt;sup>8</sup> A total of 59 children were missing a CRP value (51 with mild/moderate disease and 8 with severe disease) resulting in a total N of 263.

<sup>&</sup>lt;sup>9</sup> The highest ferritin value measured variable used and a total of 219 children were missing a value (185 with mild/moderate disease and 34 with severe disease) resulting in a total N of 103.

 $<sup>^{10}</sup>$  A total of 250 children were missing albumin values (198 with mild/moderate disease and 52 with severe disease) resulting in a total N of 72.

**eTable 8.** Multivariable logistic regression models among non-MIS-C patients for factors associated with severe PCR-positive SARS-CoV-2 infection (WHO COVID-19 clinical progression scale of  $\geq$ 6).

Model 1 incorporates the number of comorbidities, model 2 selected individual comorbidities.

Covariates	Model 1 aOR (95% CI)	Model 2 aOR (95% CI)
<1 year	Ref.	Ref.
1-4 years	1.00 (0.41-2.47)	1.04 (0.43-2.52)
5-11 years	0.36 (0.11-1.18)	0.31 (0.09-1.08)
≥12 years	0.86 (0.35-2.14)	0.62 (0.23-1.70)
Number of comorbidities		
None	Ref.	-
1 comorbidity	2.04 (0.92-4.54)	-
Multiple ( <u>&gt;</u> 2) comorbidities	2.72 (1.16-6.39)	-
Individual comorbidities		
Obesity	-	2.67 (1.00-7.15)
Neurological disorder	-	4.39 (1.88-10.28)
Coinfections		-
Bacterial and/or viral	2.56 (1.17-5.59)	2.84 (1.28-6.30)
Imaging		
No chest imaging done	0.47 (0.09-2.36)	0.43 (0.08-2.22)
CXR and/or CT normal or had findings unrelated to COVID-19	Ref.	Ref.
CXR or CT abnormalities compatible with COVID-19	3.05 (1.38-6.71)	3.03 (1.36-6.77)
Clinical presentation		
Shortness of breath	5.17 (2.28-11.69)	4.92 (2.12-11.41)
Laboratory investigations		, ,
Neutrophilia	1.89 (0.91-3.92)	1.98 (0.94-4.20)

aOR adjusted odds ratio; CI confidence interval; CRP C-reactive protein; CT computed tomography; CXR chest x-ray